In this regard, it has recently been described that LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin [17], suggesting that patients harboring BRAFV600E mutations and LKB1 deficient could benefit from this therapy. The gene discussed is STK11; the disease is non-small cell lung carcinoma.